Skip to main content
. 2014 Jul 29;16(4):R160. doi: 10.1186/ar4675

Figure 3.

Figure 3

Clinical response to treatment is independent of the presence of antiadalimumab antidrug antibodies. Antiadalimumab antidrug antibodies (ADAbs) at the end of treatment, 2 weeks after the last injection, were not different between patients treated with 12 vs. 24 weeks of adalimumab (A) or between responders vs. nonresponders (B).